Correspondence 0001104659-24-132412 from CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738) (CASIF)

CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)
Date: Dec. 30, 2024 · CIK: 0001962738 · Accession: 0001104659-24-132412

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-283998

Date

December 30, 2024

Author

Not clearly detected

Form

CORRESP

Company

CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)

Letter

VIA EDGAR Division of Corporation Finance Office of Life Sciences CASI Pharmaceuticals, Inc. Registration Statement on Form F-3 Filed on December 20, 2024 File No. 333-283998

Dear Mr. Gorsky:

In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, CASI Pharmaceuticals, Inc. hereby requests that the effectiveness of the registration statement on Form F-3 (File No. 333-283998), initially filed with the U.S. Securities and Exchange Commission on December 20, 2024, as amended by Pre-Effective Amendment No. 1 filed on December 23, 2024, be accelerated so that the registration statement becomes effective at 10:00 a.m. Eastern Time on December 31, 2024 or as soon thereafter as practicable.

If you have any questions or comments, please contact C. Christopher Murillo of Harter Secrest & Emery LLP at (585) 231-1396.

Very truly yours,
CASI Pharmaceuticals, Inc.

Show Raw Text

CORRESP
1
filename1.htm

CASI PHARMACEUTICALS, INC.

1701-1702, China Central Office Tower 1

No. 81 Jianguo Road Chaoyang District

Beijing, 100025

People’s Republic of China

December 30, 2024

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attn: Joshua Gorsky

    Re:

    CASI Pharmaceuticals, Inc.

    Registration Statement on Form F-3

    Filed on December 20, 2024

    File No. 333-283998

Dear Mr. Gorsky:

In accordance with Rule 461
promulgated under the Securities Act of 1933, as amended, CASI Pharmaceuticals, Inc. hereby requests that the effectiveness of the registration
statement on Form F-3 (File No. 333-283998), initially filed with the U.S. Securities and Exchange Commission on December 20, 2024,
as amended by Pre-Effective Amendment No. 1 filed on December 23, 2024, be accelerated so that the registration statement becomes effective
at 10:00 a.m. Eastern Time on December 31, 2024 or as soon thereafter as practicable.

If you have any questions
or comments, please contact C. Christopher Murillo of Harter Secrest & Emery LLP at (585) 231-1396.

    Very truly yours,

    CASI Pharmaceuticals, Inc.

    By:
    /s/ Daniel Lang

    Daniel Lang

    Chief Financial Officer

SecProbe.io